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Abstract: This study examined the association of estrogen receptor alpha gene (ESR1) 
polymorphisms with cardiorespiratory and metabolic parameters in young women. In total, 
354 healthy women were selected for cardiopulmonary exercise testing and short-term 
heart rate (HR) variability (HRV) evaluation. The HRV analysis was determined by the 
temporal indices rMSSD (square root of the mean squared differences of successive R–R 
intervals (RRi) divided by the number of RRi minus one), SDNN (root mean square of 
differences from mean RRi, divided by the number of RRi) and power spectrum 
components by low frequency (LF), high frequency (HF) and LF/HF ratio. Blood samples 
were obtained for serum lipids, estradiol and DNA extraction. ESR1 rs2234693 and 
rs9340799 polymorphisms were analyzed by PCR and fragment restriction analysis. HR 
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and oxygen uptake (VO2) values did not differ between the ESR1 polymorphisms with 
respect to autonomic modulation. We not find a relationship between ESR1 T–A, T–G,  
C–A and C–G haplotypes and cardiorespiratory and metabolic variables. Multiple linear 
regression analysis demonstrated that VO2, total cholesterol and triglycerides influence HRV 
(p < 0.05). The results suggest that ESR1 variants have no effect on cardiorespiratory  
and metabolic variables, while HRV indices are influenced by aerobic capacity and lipids in 
healthy women. 
Keywords: estrogen receptor-α gene polymorphisms; heart rate variability;  
aerobic capacity; lipids 
 
1. Introduction 
Estrogens are important steroid hormones that influence multiple organ systems in both men and 
women, including cardiovascular, reproductive and skeletal muscle systems [1]. The effects of 
estrogens on the cardiovascular system are mediated mainly through the estrogen receptor (ER), 
which is a member of the nuclear hormone receptor superfamily and acts as a ligand-activated 
transcription factor [2,3]. Within the central nervous system, ER alpha is found in the preganglionic 
autonomic centers of the brain stem that are involved in cardiovascular regulation [4]. The autonomic 
nervous system plays a role in controlling the heart rate (HR) and vascular tonus, thereby helping 
to maintain homeostasis [3–5] and influencing cardiorespiratory capacity [6–9] and lipid profiles [10–12]. 
Association of the autonomic nervous system on the heart has been widely studied for the analyses 
of heart rate variability (HRV). HRV has previously been associated with aerobic capacity. 
Hedelin et al. [6] found that VO2 peak is moderately and positively correlated with the high frequency 
band of HRV. This effect is attributed to parasympathetic modulation. In addition, Kouidi et al. [8] 
stated that autonomic adaptations of HR at rest are intrinsically linked with peak VO2. However, 
Loimaala et al. [9] claim that the highest HRV indices may not be linked to high aerobic capacity. 
Metabolic variables, such as cholesterolemia, have been associated with low HRV. Previous studies 
have shown an inverse relationship between low HRV indices and high serum levels of total and LDL 
cholesterol in men with ischemic heart disease [10] and patients with coronary artery disease [11]. 
In addition, studies have shown that variations in plasma lipids depend on estrogen levels [13,14]. 
In women with augmented estrogen levels, Yildizhan et al. [14] observed both an increase in the 
levels of triglycerides and a reduction of HDL cholesterol in plasma. Estrogen receptor-mediated 
actions induce an increase in the metabolism of glucose and fat mass [15,16] and the regulation 
of peripheral vasodilation [2,15,17]. Both of these parameters are closely related to aerobic capacity [12]. 
The ESR1 rs2234693 and rs9340799 polymorphisms have been reported as interfering with the 
action of the estrogen receptor [14–16], leading to the development of risk factors for cardiovascular 
disease, such as dyslipidemia, insulin resistance, hypertension, central obesity and type 2  
diabetes [1,2,18–21]. Autonomic modulation of HR has been evaluated only in one study, which 
showed that the ESR1 rs2234693 and rs9340799 polymorphisms in young healthy men are 
associated with a lower HRV, resulting from reduced parasympathetic autonomic modulation of HR [22]. 
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On the other hand, the association of these genetic variants on the autonomic modulation of HR 
in women has not been described. 
Although there is evidence that autonomic modulation of HR has been related to aerobic capacity [6,7], 
lipid profile parameters [10,11] and ESR1 polymorphisms [2,18–22] in different sample populations, 
these associations in healthy young women have not been investigated. Therefore, this study 
investigated the relationship between the ESR1 rs2234693 and rs9340799 polymorphisms and HRV, 
aerobic capacity and serum lipid profiles in young women. 
2. Results and Discussion 
The demographic characteristics, baseline cardiovascular data, functional aerobic classification and 
results of the blood and urine biochemical tests are shown in Table 1. These values are within the 
normal range for healthy young women. 
Table 1. Demographic, clinical data and metabolic variables of young women (n = 354). 
Demographic and clinical data Metabolic variables 
Age, years 26 ± 4 Glucose, mg/dL 71 ± 9 
Body mass, kg 72 ± 2 Urea, mg/dL 0.54 ± 0.1 
Height, cm 68 ± 13 Creatinine, mg/dL 0.6 ± 0.5 
BMI, kg/m2 21 ± 3 Total cholesterol, mg/dL 161.2 ± 18 
HR supine, bpm 60 ± 5 LDL cholesterol, mg/dL 96.0 ± 21 
HR sitting, bpm 74 ± 10 HDL cholesterol, mg/dL 45.8 ± 10 
SBP supine, mmHg 110 ± 4 Triglycerides, mg/dL 73.0± 22 
DBP supine, mmHg 75 ± 3 Progesterone, ng/mL 1.84 ± 6 
SBP sitting, mmHg 115 ± 3 Estradiol, pg/mL 101.9 ± 56 
DBP sitting, mmHg 72 ± 3 Aerobic classification AHA Regular 
Values are shown as the mean ± standard deviation; BMI: body mass index; HR: heart rate; SBP: systolic blood pressure; 
DBP: diastolic blood pressure; HDL: high density lipoprotein; LDL: low density lipoprotein; AHA: American  
Heart Association. 
Minor allele frequencies for ESR1 c.454-397T > C and c.454-351A > G in the study group were 
41.2% and 39.4%, respectively (Table 2). The genotype distributions were as expected from the 
Hardy-Weinberg equilibrium. A strong linkage disequilibrium was observed between the ESR1  
c.454- 351A > G and c.454-397T > C polymorphisms (Lewontin's coefficient: D’ = 0.823; p = 0.001) 
and four haplotypes were detected in the sample. The most frequent haplotype (AT) was present in 
59.2% of the studied chromosomes, whereas haplotypes GC, GT and AC had frequencies of 35.7%, 
5.7% and 3.9%, respectively (Table 2).  
Table 2. Frequencies of ESR1 polymorphisms in young women. 
Polymorphisms Genotypes Alleles 


































Number of individuals is in parentheses. 
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Table 3. Relationship of ESR1 polymorphisms with HRV and VO2 indices and metabolic variables in young women. 
Variables  
c.454-397T > C genotypes  c.454-351A > G genotypes  
TT (n = 144) TC (n = 128) CC (n = 82) p AA (n = 150) AG (n = 129) GG (n = 75) p 
HRV and VO2 indices         
rMSSD, ms2 53.79 ± 34.39 53.42 ± 29.37 53.40 ± 41.82 0.43 53.13 ± 33.70 51.92 ± 31.40 53.16 ± 45.00 0.27 
SDNN, ms2 55.54 ± 25.27 54.78 ± 23.83 57.34 ± 35.57 0.23 55.88 ± 26.17 53.36 ± 24.88 54.93 ± 37.39 0.24 
LF, nu 0.45 ± 0.17 0.43 ± 0.16 0.46 ± 0.16 0.25 0.45 ± 0.17 0.44 ± 0.16 0.44 ± 0.18 0.27 
HF, nu 0.54 ± 0.17 0.56 ± 0.16 0.53 ± 0.16 0.19 0.54 ± 0.17 0.55 ± 0.17 0.55 ± 0.18 0.71 
LF/HF ratio 1.08 ± 0.87 1.01 ± 0.94 1.12 ± 1.02 0.21 1.06 ± 0.86 1.03 ± 0.88 1.07 ± 1.08 0.33 
VO2, mL·kg−1·min−1 26.28 ± 5.53 27.24 ± 6.23 26.46 ± 15.60 0.12 25.66 ± 5.57 26.86 ± 5.88 26.46 ± 5.35 0.43 
Metabolic         
Total cholesterol, mg/dL 166 ± 32 165 ± 35 161.6 ± 39 0.12 164 ± 34 164 ± 35 164 ± 39 0.19 
HDL cholesterol, mg/dL 44 ± 13 45 ± 12 42 ± 9 0.14 44 ± 11 44 ± 12 43 ± 10 0.27 
LDL cholesterol, mg/dL 98 ± 32 102 ± 37 97 ± 40 0.22 98 ± 33 100 ± 35 100 ± 41 0.32 
Triglycerides, mg/dL 88 ± 47 85 ± 36 89 ± 59 0.43 84 ± 45 88 ± 41 89 ± 61 0.27 
Data are shown as the mean ± standard deviation and compared by an analysis of variance (ANOVA) rank test. HRV: Heart rate variability; VO2: Oxygen uptake during peak exercise; 
rMSSD: square root of the mean of the sum of the squares of differences between adjacent RRi divided by the number of RRi minus one, expressed in ms); SDNN: square root of the sum of 
the squares of differences of individual values compared to the mean value, divided by the number of RRi in a period; LF: low frequency; HF: high frequency; ms2: square milliseconds;  
nu: normalized units. HDL: high-density lipoprotein; LDL: low-density lipoprotein. 
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The relationship between ESR1 polymorphisms and cardiorespiratory and metabolic variables is 
shown in Table 3. The supine HRV indices in both the time domain (TD) and frequency domain (FD) 
(rMSSD, SDNN, LF, HF, LF/HF) were similar for all the genotypes. In addition, VO2 during peak 
CPET, which represents aerobic capacity, did not vary significantly between the genotypes 
investigated. Lipids (total cholesterol, triglycerides, LDL cholesterol and HDL cholesterol) levels were 
similar for the genotypes of both ESR1 polymorphisms (c.454-397T > C and c.454-351A > G).  
The present study demonstrated that these ESR1 variants have no influence on cardiorespiratory and 
metabolic variables in healthy young women. A linear regression was performed to show that 
functional aerobic capacity and serum lipids had more of a direct association with HRV than genetic 
changes. Similarly, no association was found between the ESR1 haplotypes and cardiorespiratory and 
metabolic variables (data not shown). Multiple linear regression analysis was used to evaluate the 
influence of peak VO2, HDL cholesterol, LDL cholesterol and triglycerides on HRV indices (Table 4). 
VO2 peak was positively related with rMSSD, SDNN and HF and negatively correlated with LF  
(p < 0.05). Triglycerides and total cholesterol were negatively correlated with rMSSD, SDNN, LF and 
HF, indicating that a relationship exists between these parameters and the autonomic modulation of 
responses. All the models built satisfied the hypotheses of homoscedasticity and normality of residuals. 
Table 4. Multiple linear regression analysis of variables (VO2 and lipids) that influence HRV indices. 
HRV  
indices 
Aerobic capacity  
VO2 
Lipids 
HDL cholesterol LDL cholesterol Total Cholesterol Triglycerides  
B p B p B p B p B p R2 
rMSSD 1.40 0.003 0.24 0.200 −0.10 0.290 −0.18 0.004 −1.79 0.020 48% 
SDNN 1.01 0.001 0.08 0.590 −0.10 0.240 −0.15 0.002 −0.19 0.010 30% 
LF −1.73 0.010 −2.96 0.040 −0.09 0.960 −0.06 0.13 0.39 0.840 34% 
HF 19.18 0.004 2.10 0.280 −0.01 0.700 −0.06 0.03 −2.45 0.150 42% 
rMSSD: square root of the mean of the sum of the squares of differences between adjacent RRi divided by the number of 
RRi minus one, expressed in ms; SDNN: square root of the sum of the squares of differences of individual values 
compared to the mean value, divided by the number of RRi in a period; LF: low frequency; HF: high frequency;  
VO2: oxygen uptake during peak exercise; B: regression coefficient; R2: determination coefficient. 
Our results show a lack of association between ESR1 polymorphisms (rs2234693 and rs9340799) 
and HRV indices analyzed in the time and frequency domains. These findings contrast those of 
Matsunaga et al. [22], who reported that these ESR1 polymorphisms are associated with reduced 
autonomic control of HR in Japanese men in the time and frequency domains. This association could 
be a predictor for episodes of cardiovascular disease. Differences regarding the methods of signal 
processing and analysis of heart rate variability, type of experimental design and sample composition 
may have contributed to the different results obtained between Matsunaga’s study and ours.  
Matsunaga et al. [22] evaluated only young Japanese males who underwent ECG recording and power 
spectral analysis of HRV in the standing and supine position; however, the present study evaluated 
healthy young women in the supine position. Therefore, the common mechanisms of the molecular 
relationship between ESR1 polymorphisms and the autonomic modulation of HR in healthy young 
women should be further explored. These results do not exclude the hypothesis that ESR1 variants may 
contribute to the mechanism involved in the modulation of HR, but large-scale studies in other 
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populations are needed to elucidate the influence of the ESR1 rs2234693 and rs9340799 
polymorphisms on the autonomic modulation of HR phenotypes. 
In the present study, no relationship was found between ESR1 genotypes and the serum lipid 
profile. Some studies have evaluated the impact of ESR1 polymorphisms (rs2234693 and rs9340799) 
on basal serum lipids in patients with coronary artery disease (CAD) [2,21,23], including healthy 
females at peak reproductive age [24,25], postmenopausal females [20,26] and premenopausal female 
smokers [27]. In Iranian population with symptoms related to CAD subgroups of patients stratified by 
gender, Boroumand et al. [2] observed no effects of ESR1 c.454-39T > C and c.454-351A > G variants 
on serum lipids and lipoprotein(a) levels. On the other hand, Molvarec et al. [24] reported that the total 
cholesterol concentrations in serum samples were significantly higher in healthy women carrying the 
ESR1 c.454-39CC genotype than in those with the TT or TC genotypes. Whereas healthy women 
carriers of the c.454-351GG genotype had significantly higher total cholesterol and LDL cholesterol 
levels in serum samples compared to those with the AA or AG genotype in healthy Caucasian women 
and men of reproductive age. In this study, no differences were found in LDL, HDL, total cholesterol 
and triglyceride levels among carriers of genotypes for ESR1 c.454-39T > C and c.454-351A > G 
variants, indicating that the relationship between the polymorphisms and lipid profiles of the 
mentioned studies depends on parameters of the experimental model, such as medication, gender, age 
and risk factors for CAD. Intronic polymorphisms are also known to modify the splicing of messenger 
RNA (mRNA) transcripts, resulting in significant changes in gene function. However, how the 
molecular mechanism of the C allele is associated with augmented estrogen action with respect to 
HDL cholesterol remains unclear. The single-nucleotide polymorphisms (SNPs) may be merely linked 
to another as-yet-unidentified causative sequence variant.  
We also do not found any relationship between the ESR1 c.454-39T > C and c.454-351A > G 
polymorphisms and peak VO2 during CPET and HRV at rest. The interaction of estrogen with ER 
alpha promotes peripheral vasodilatation, an effect that can contribute to an increase in functional 
aerobic capacity at peak effort. However, Gurd et al. [28] suggest that estrogen metabolism does not 
interfere with O2 uptake by muscle, as determined by deoxyhemoglobin/myoglobin (Delta HHb) 
values. Campbell et  al .  [29] found that postmenopausal women using estrogen hormone 
replacement therapy did not show an improvement in VO2 during physical training and that their 
estradiol levels remained unchanged. Molvarec et al. [24] demonstrated that healthy subjects at  
peak reproductive age who were carriers of the T and/or A alleles of ERS1 SNPs (the recessive 
inheritance model) had higher estradiol levels, which is a protective factor against cardiovascular 
disease, as estrogen promotes ERα-mediated peripheral vasodilatation. Despite the cross-sectional 
nature and the sample size evaluated, some parameters were not controlled, which may have 
influenced the results of the study. In contrast, our study subjects were composed of only young 
healthy women who showed no change in aerobic capacity at peak VO2. When compared with other 
studies, the difference in the results may also be explained by the age of the participants and the 
experimental design. 
Reduction of HRV, changes in the metabolism of plasma lipids and reduction in functional aerobic 
capacity are important risk factors for the development of CAD [11]. However, few studies have 
observed the relationship between HRV indices and healthy young women’s lipid profiles and aerobic 
capacities [10,12]. Thus, in the present study, linear regression revealed a significant correlation 
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between VO2 during peak exercise and HRV indices. This finding suggests that increases in aerobic 
capacity are related to central adaptations and the autonomic modulation of HR. Kouidi et al. [8] found 
that autonomic modulation of HR at rest are intrinsically linked to functional aerobic capacity, which 
depends on the individual’s physical condition. However, according to Loimaala et al. [9], higher 
HRV indices may not be related to VO2, but rather may be related to microcirculation in the 
autonomic nervous system. The results suggest a relationship exists between resting HRV and 
functional aerobic capacity. These findings corroborate those of Hedelin et al. [6], Hautala et al. [7] 
and Aubert et al., [30] all of whom reported that peak VO2 has a moderate positive correlation with 
the HF range, which suggests parasympathetic modulation. These authors also report that the lower 
values of BF correspond to central and peripheral adaptations, indicating that the reduction in 
sympathetic modulation is associated with gains in muscle performance, muscle blood flow and VO2 
peak. Thus, the results suggest a relationship between the dynamics of HRV at rest with functional 
aerobic capacity. 
We observed a significant and negative correlation between triglycerides and indices of autonomic 
modulation of HR (rMSSD, SDNN and HF). Other authors have observed an inverse relationship 
between HRV indices and total cholesterol and LDL values, both in patients with CAD [10,11] and in 
healthy young women [12]. In a study by Christensen et al. [10], men with CAD and healthy 
sedentary men were evaluated for the association between HRV indices and cholesterol. In both 
groups, total cholesterol and LDL were inversely associated with indices of HRV, i.e., low levels 
of HRV are associated with high cholesterol levels. Researchers investigating the association 
between short-term HRV and cholesterol levels in both genders without heart disease found that the 
rMSSD was inversely related to LDL cholesterol [10–12]. Even though vagal tone (baroreflex 
sensitivity) and HRV have been shown to be reduced in individuals with a family history of 
dyslipidemia [11], the mechanism by which circulating lipids association HRV remains to be 
elucidated. Risk factors including a lack of physical activity and the abuse of tobacco, alcohol and 
drugs have also been associated with changes in lipid profiles, autonomic imbalance and decreased 
parasympathetic modulation [11]. On the other hand, regular physical training promoted the 
effective regulation of the autonomic nervous system, promoting an increase in parasympathetic 
modulation and a reduction of sympathetic modulation [31]. 
In order to maximize the vascular benefits on blood vessels in women with postmenopausal CVD, 
the potential interaction of estrogen with progesterone and testosterone and its effects on vascular 
function may need to be considered [31]. In summary, the results of the present study suggest that VO2 
may be associated with indices of autonomic modulation of HR (rMSSD, SDNN and HF). Thus, 
regular physical training promoted an increase in parasympathetic modulation and a reduction of 
sympathetic modulation. 
3. Experimental Section 
3.1. Subjects and Study Design 
The sample size was calculated by establishing an error of 10% and a power of 80% and using 
the higher allele frequency of the studied polymorphism described by previous works evaluating a 
Int. J. Mol. Sci. 2012, 13 13698 
 
 
Brazilian population [20]. Four hundred and forty-five healthy women who were 18 to 38 years old 
and self-described non-Africans (www.ibge.gov.br/) were selected for the study after being recruited 
through an advertisement campaign in gyms and clubs. Forty-nine participants were excluded and 
fifteen refused to participate. Twenty-two did not meet the inclusion criteria, twelve were missing data 
on one or more of the variables of interest (or had incomplete genotyping). These individuals had 
regular menstrual cycles and ovulation, which was confirmed by a serum progesterone concentration 
above 4.0 mg/mL on the 21st day of the menstrual cycle. An evaluation form on daily habits, 
previous family history of existing pathologies, use of oral contraceptives (OCs) and physical 
activity level was completed. All subjects were in good health, and their biochemical parameters  
were within normal range. Subjects showing clinical evidence and/or biochemical signs of 
hyperandrogenism, cardiac or respiratory disease, hypertension (blood pressure ≥140/90 mmHg), 
diabetes mellitus, thromboembolic disease, thyroid diseases, stroke, depression, or problem drinking 
and smoking were excluded from the study. None of the subjects were taking sedatives, 
antihypertensives, antiarrhythmics or any other medications that could affect the autonomic control of 
HR. The study was approved by the Ethics Committee of the Methodist University of Piracicaba, 
SP, Brazil (protocol # 43/06). All participants provided written informed consent. 
3.1.1. Clinical and Biochemical Assessment 
All subjects underwent a clinical examination between the 7th and 10th day after the first day of 
menstruation. The body mass index (BMI) for each subject was calculated after the weight and height 
were measured. Resting HR was measured with a 12-lead electrocardiogram (ECG), and a 
cardiopulmonary exercise test was conducted using cardiac auscultation. HR and blood pressure (BP) 
were measured after 5 min of rest in the supine and sitting positions by the Korotkoff auscultatory 
method, using a mercury-column sphygmomanometer (WanMed São Paulo, SP, Brazil) and a 
stethoscope (Littman, St. Paul, MN, USA). These measurements were repeated every two minutes 
after the initial measurements were made and during two separate visits to the laboratory. For 
biochemical measurements, venous blood samples were drawn after a 12-h overnight fast. Serum 
glucose was measured by the glucose oxidase method. Levels of total cholesterol, high density 
lipoprotein (HDL) cholesterol, triglycerides, estrogen, progesterone, urea, and creatinine were 
determined by enzymatic colorimetric assays (BioSystems Biotecnica kit, Barcelona, Spain). For 
triglyceride values that were less than 400 mg/dL, low density lipoprotein (LDL) cholesterol was 
estimated using Friedewald’s formula.  
3.1.2. Clinical and Biochemical Assessment 
A cardiopulmonary exercise test was carried out on a cycle ergometer (Quinton Corival 400, 
Seattle, WA, USA) with increments of 20 to 25 W·min−1 up to physical exhaustion.  
Physical exhaustion corresponded to an inability to keep up the speed of 60 rpm, the occurrence  
of a limiting symptom or the occurrence of respiratory fatigue. Power output increases  
were determined for each subject according to the following formula: power output increase  
(W) = [(height − age) × 14] − [150 + (6 × body mass)]/100 [32]. Ventilatory and metabolic 
measurements were obtained on a breath-by-breath basis using a specific metabolic analyzer  
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(CPX/D MedGraphics Breeze, St. Paul, MN, USA). Aerobic capacity was then evaluated using 
absolute VO2 (mL·kg−1·min−1), which was obtained at the peak of the exercise test. 
3.2. Heart Rate Variability Analysis 
ECG and HRV were recorded beat to beat on a one-channel heart monitor (MINISCOPE II 
Instramed, Porto Alegre, RS, Brazil) and processed with an analog-to-digital converter (Lab PC+, 
National Instruments, Co., Austin, TX, USA), which acted as an interface between the heart monitor 
and a microcomputer. The ECG signal was recorded in real time after the analog-to-digital conversion 
at a sampling rate of 500 Hz [33]. The interval between an R wave and the next R wave (RR) was 
analyzed using 256 consecutive heart beats from the most stable section. The HRV analysis was 
carried out using linear methods. In the time domain, the temporal indices rMSSD (the square root of 
the mean squared differences of successive RRi divided by the number of RRi minus one, expressed in 
ms) and SDNN (root mean square of differences from mean R–R interval, divided by the number of 
RRi of the period selected) was used. In the frequency domain, a nonparametric method involving fast 
Fourier transformation of the previously selected RRi was used. Using power spectrum components, 
very low frequency (VLF: 0.003 to 0.04 Hz), low frequency (LF: 0.04 to 0.15 Hz) and high frequency 
(HF: 0.15 to 0.4 Hz) signals were obtained, as was the ratio between absolute low frequency and  
high-frequency areas (LF/HF ratio). Normalization was carried out by dividing the absolute power of 
ms2 (LF or HF) by the total power spectrum, subtracting the VLF component and multiplying by 100. 
HF and LF bands represent the action of parasympathetic and predominantly sympathetic components 
of HR regulation, respectively. The data were analyzed in MATLAB 6.5 using the HRV analysis 
routine [34]. 
3.3. Genotyping 
DNA was isolated from white blood cells using the salting-out procedure [35]. ESR1 c.454-397T > C 
(IVS1-397T > C, rs2234693) and c.454-351A > G (IVS1-351A > G, rs9340799) polymorphisms were 
determined using polymerase chain reaction (PCR) and restriction fragment analysis as previously 
described [19,20]. PCR assays were carried out in a Biometra T Gradient (Whatman Biometra, 
Göttingen, Germany) using the following cycling program: one cycle at 94 °C for 1 min, 30 cycles at 
94 °C for 1 min 30 s, 62 °C for 1 min, and 72 °C for 90 s and one cycle at 72 °C for 10 min. PCR 
products were treated with endonucleases PvuII and XbaI (Invitrogen, São Paulo, SP, Brazil). 
Restriction fragments (PvuII: 936 bp and 438 bp; XbaI: 981 bp and 396 bp) were analyzed by 1% 
agarose gel electrophoresis. Genotyping quality control was performed as described in detail 
elsewhere [36]. All genotypes were determined by two independent technicians and the results 
were entered in the database in duplicate. Ten percent of the samples were randomly reanalyzed. 
3.4. Statistical Analysis 
The allele frequencies and genotype distribution were estimated by gene counting. The Hardy-Weinberg 
equilibrium was assessed by the chi-square test using Arlequin v3.11 software, which uses an 
expectation-maximization algorithm. Linkage disequilibrium (LD) and haplotype frequencies were 
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estimated using the Lewontin’s D’ coefficient from each pair of polymorphisms and Haploview 4.2 
software. SPSS v.16 was used to compare frequencies among the groups, adjusted residuals and the 
power of the test. The association between genotype groups and levels of cardiorespiratory and 
metabolic variables was analyzed using analysis of variance (ANOVA) with LSD’s correction for 
multiple comparisons. Multiple linear regression analysis was used to investigate the relationship 
between HRV indices and clinically relevant covariants: the functional aerobic capacity and the lipid 
profile. A minimum coefficient of determination (R2) of 30% and a variation of <0.03 were considered. 
4. Conclusions  
In summary, this study demonstrates the lack of an association between the ESR1 polymorphisms 
and HRV indices, aerobic capacity, serum estradiol, progesterone and lipid profiles. This finding 
demonstrated that these ESR1 variants have no association on cardiorespiratory and metabolic 
variables in young healthy women and suggested that they may not be implicated in cardiovascular 
risk in young women. However, the results also suggested that functional aerobic capacity and serum 
lipids may have an association with HRV indices. 
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